修和方加减联合TC 化疗治疗中晚期卵巢癌临床研究
DOI:
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R737.31

基金项目:


Clinical Study on Modified Xiuhe Prescription Combined with TC Chemotherapy for Ovarian Cancer in Middle and Late Stage
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察修和方加减联合TC (紫杉醇+卡铂) 化疗治疗中晚期卵巢癌的临床疗效。方法:将 74 例中晚期卵巢癌(气血亏虚证) 患者按随机数字表法分为对照组和观察组各37 例。对照组予以TC 化疗, 观察组在对照组基础上给予修和方加减治疗,均治疗12 周。评价2 组临床疗效,比较2 组治疗前后中医证候 评分、肿瘤标志物水平及免疫功能,统计2 组不良反应发生情况。结果:观察组总有效率高于对照组,差异有 统计学意义(P<0.05)。治疗后,2 组主症、次症评分和总分均低于治疗前(P<0.05),且观察组主症、次症 评分和总分均低于对照组(P<0.05)。治疗后,2 组血清甲胎蛋白(AFP)、糖链抗原125(CA125)、糖链抗原 153 (CA153) 水平均低于治疗前(P<0.05),且观察组血清AFP、CA125、CA153 水平均低于对照组(P< 0.05)。治疗后,对照组CD3+、CD4+、CD4+/CD8+水平均低于治疗前(P<0.05),观察组治疗后CD3+、CD4+、 CD4+/CD8+水平均高于对照组(P<0.05)。观察组骨髓抑制发生率低于对照组(P<0.05)。结论:修和方加减 联合TC 化疗可减轻中晚期卵巢癌患者的临床症状,增强抗癌效果,控制血清肿瘤标志物水平,避免T 细胞免 疫功能下降,减少骨髓抑制。

    Abstract:

    Abstract : Objective : To observe the clinical effect of modified Xiuhe Prescription combined with TC (taxol+carboplatin) chemotherapy for ovarian cancer in middle and late stage. Methods : A total of 74 patients with ovarian cancer in middle and late stage with deficiency of qi and blood syndrome were divided into the control group and the observation group according to the random number table method, with 37 cases in each group. The control group was given TC chemotherapy ,and the observation group was additionally treated with modified Xiuhe Prescription based on the treatment of the control group. Both groups were treated for 12 weeks. The clinical effects in the two groups were evaluated. Before and after treatment,traditional Chinese medicine syndrome scores,levels of tumor markers and immune function were compared between the two groups. The incidence of adverse reactions in the two groups was counted. Results: The total effective rate in the observation group was higher than that in the control group, the difference being significant (P<0.05). After treatment, the scores of main and secondary symptoms and the total scores in the two groups were lower than those before treatment (P<0.05),and the scores of main and secondary symptoms and the total scores in the observation group were lower than those in the control group (P<0.05). After treatment,the levels of alpha-fetoprotein (AFP),carbohydrate antigen 125 (CA125),and carbohydrate antigen 153 (CA153) in serum in the two groups were lower than those before treatment (P<0.05),and the levels of AFP,CA125 and CA153 in serum in the observation group were lower than those in the control group (P<0.05). After treatment,the levels of CD3+,CD4+ and CD4+/CD8+ in the control group were lower than those before treatment (P<0.05),and the levels of CD3+, CD4 + and CD4 +/CD8 + in the observation group were higher than those in the control group (P<0.05). The incidence of myelosuppression in the observation group was lower than that in the control group (P<0.05). Conclusion:Modified Xiuhe Prescription combined with TC chemotherapy can reduce clinical symptoms in patients with ovarian cancer in middle and late stage,improve anti- cancer effect,inhibit levels of tumor markers in serum,avoid the decline of immune function of T cells,and reduce myelosuppression.

    参考文献
    相似文献
    引证文献
引用本文

李惠,陈俊,张娥.修和方加减联合TC 化疗治疗中晚期卵巢癌临床研究[J].新中医,2023,55(9):165-169

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2023-05-24
  • 出版日期:
文章二维码